Synairgen PLC
LSE:SNG

Watchlist Manager
Synairgen PLC Logo
Synairgen PLC
LSE:SNG
Watchlist
Price: 0.95 GBX Market Closed
Market Cap: 10.5m GBX

Operating Margin
Synairgen PLC

0%
Current
0%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-8.7m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Synairgen PLC
LSE:SNG
10.5m GBP N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
393.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.9B AUD
26%
NL
argenx SE
XBRU:ARGX
44.5B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD
8%
No Stocks Found

Synairgen PLC
Glance View

Market Cap
10.5m GBX
Industry
Biotechnology

Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The firm is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The firm is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The firm offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

SNG Intrinsic Value
0.78 GBX
Overvaluation 18%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-8.7m
/
Revenue
0
What is the Operating Margin of Synairgen PLC?

Based on Synairgen PLC's most recent financial statements, the company has Operating Margin of 0%.

Back to Top